MedTrace Logo

Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH

NCT02631421 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2019-07-16

No results posted yet for this study

Summary

Right ventricular (RV) failure is the predominant cause of death in pulmonary arterial hypertension (PAH). No RV-specific therapies are available, in part because the underlying mechanisms of RV dysfunction are poorly understood. Given the heart's preference for fatty acids (FA) as an energy source, a deeper understanding of FA metabolism may shed light on RV adaptation to elevated afterload in PAH. The purpose of this study is to test the hypothesis that defects in fatty acid metabolism are common in PAH and contribute to RV failure. The investigators will measure peripheral and transcardiac lipid and glucose metabolites in PAH patients in comparison with patients with pulmonary venous hypertension and no evidence of pulmonary hypertension. The investigators will also correlate metabolites with concurrent measurement of right ventricular function.

Conditions

Interventions

PROCEDURE

Blood Sampling

OTHER

Cardiac MRI

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Evan Brittain, MD, MSCI · Vanderbilt Univerisy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631421 on ClinicalTrials.gov